There are currently 999 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
NCT06253845
Recruiting
Investigators will evaluate the safety of CG0070 for the treatment of patients with Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692
Recruiting
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
NCT06833502
Recruiting
The purpose of the study is to determine the frequency of systemic metastasis in node positive breast cancer following chemotherapy and surgery. Participants will be asked to spend about 6 months in this study. Participants will undergo a computed tomography (CT) screening of the thorax, abdomen, and pelvis at baseline prior to adjuvant radiation therapy and another CT screening of the thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Node-positive Breast Cancer
Register for Updates
NutritiOUs fRuIts and veggieS to Improve Health: A Culinary Medicine Intervention
NCT06926972
Recruiting
This study includes a 12-week culinary medicine intervention integrated within the existing YMCA Suncoast Survivorship and Wellness Program Powered by Moffitt. Members of the John Geigle YMCA will be assigned to the NOURISH intervention, which includes biweekly provision of fruit and vegetable bundles, recipe cards, and nutritional education handouts plus 30-minute culinary medicine demonstrations with skill-building training (six total demonstrations focused on fruit and vegetable recipes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Cancer, Nos
Register for Updates
SHARE Program: SUSTAIN
NCT06934395
Recruiting
The goal of PROJECT SUSTAIN is to optimize Healthy Choices to advance an adaptive and scalable intervention designed to improve self-management of alcohol and HIV in Young People with HIV (YPWH) while understanding the context for state-wide implementation and sustainment in a Hybrid Experimental Design (HED). SUSTAIN utilizes mHealth and telehealth intervention delivery of Healthy Choices (HC), combined with text messaging between sessions, to increase the likelihood of daily medication adheren... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
06/18/2025
Locations: University of South Florida, Tampa, Florida
Conditions: Hiv
Register for Updates
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
NCT03761108
Recruiting
The main purpose of this study is to learn about the safety of REGN5458 and to find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5458 can treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving REGN5458 * How REGN5458 works in the body * How much REGN5458 is present in the blood * How REGN5458 may work to treat cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center - McKinley Drive, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05304767
Recruiting
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Interventional Psychiatry of Tampa Bay, Tampa, Florida
Conditions: Schizophrenia
Register for Updates
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411
Recruiting
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation
Register for Updates
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
NCT06435351
Recruiting
This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
NCT06497569
Recruiting
The purpose of this study is to determine how the STRONG intervention compares with usual care for reducing malnutrition among gastroesophageal cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: GastroEsophageal Cancer
Register for Updates
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
NCT06553885
Recruiting
This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Metastatic Colorectal Cancer, Hepatocellular Carcinoma
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
NCT06615557
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Vistagen Clinical Site, Tampa, Florida
Conditions: Social Anxiety Disorder (SAD)
Register for Updates